Example: bankruptcy
Timetable: Initial (full) marketing authorisation ...
The timetables in this document may be subject to revision Initial (Full) Marketing Authorisation application accelerated assessment timetables¬
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Timetable: Initial (full) marketing authorisation …
www.ema.europa.euThe timetables in this document may be subject to revision Initial (Full) Marketing Authorisation application assessment timetables: Assessment of initial submission (120-day timetable)
VICH and its role for authorisation of veterinary ...
www.oie.intPage 3 What should be included in an application ‘dossier’? A full application for a marketing authorisation would normally comprise a comprehensive data package with quality documentation, safety data (including target animal safety
Harmonised Technical Guidance for Non-eCTD …
esubmission.ema.europa.euThis guidance does not apply to the electronic submission of p-marketing authorisation (re MA) information such as scientific advice, clinical trial applications, orphan drug designations, PIP submissions and related submission
Public Assessment Report UK National Procedure …
www.mhra.gov.ukFor the full list of all side effects reported with Nefopam Hydrochloride 30mg Film-coated Tablets see section 4 of the package leaflet. For the full list …
CONSOLIDATED VERSION OF DIRECTIVE …
www.allenovery.comVersion Date – 13 August 2013 © Allen & Overy 2013 CONSOLIDATED VERSION OF DIRECTIVE 2011/61/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
Bleeding - Scottish Palliative Care Guidelines
www.palliativecareguidelines.scot.nhs.ukScottish Palliative Care Guidelines ‐ Bleeding Copyright © 2014 NHS Scotland Page 3 of 5 Issue Date: 31/05/2014 Review Date: 31/05/2017 Medication Bleeding from ...